Activating FGFR2 missense mutations or amplifications can occur in cancers of the stomach, breast, lung, endometrium, and ovary [168], and overexpression of the FGFR2b-specific ligand FGF10 is linked to worse prognosis in breast cancer [169]. This evidence concerns the gene FGFR2 and cancer.